Table 1 Overview of the diagnosis, duration of CME, and ocular and systemic treatment of the patients prior to FAc implant

1 OD/OS

M, 60

Panuveitis, rheumatoid arthritis

Cyclosporine, methotrexate, prednisolone

36 months

Multiple triamcinolone periocular, multiple dexamethasone intravitreal

2 OS

M, 50

Intermediate uveitis

Mycophenolate

36 months

Multiple triamcinolone periocular and subconjunctival, multiple dexamethasone intravitreal

3 OS

F, 25

Posterior uveitis, acute zonal outer occult retinopathy (AZOOR)

None currently, previously mycophenolate (stopped because of intolerances)

6 years

Multiple dexamethasone intravitreal, bevacizumab (1×) intravitreal

4 OD/OS

F, 48

Intermediate uveitis

None currently, previously methotrexate and mycophenolate, (mycophenolate stopped when diagnosed with malignant melanoma)

4 years

Multiple triamcinolone periocular and intravitreal, multiple dexamethasone intravitreal

5 OD/OS

F, 45

Posterior uveitis, multifocal chorioretinitis and panuveitis (MCP)

Azathioprine

6 years

Multiple triamcinolone periocular and intravitreal, multiple dexamethasone intravitreal

6 OD

M, 50

Intermediate uveitis, multiple sclerosis

Previously: high-dose corticosteroid therapy, interferon beta, fingolimod

Currently: rituximab IV every 6 to 9 months

18 months

Triamcinolone periocular (2×), dexamethasone intravitreal (2×)

7 OD

F, 37

Intermediate uveitis

Cyclosporine, methotrexate

9 years

Multiple triamcinolone subconjunctival, multiple dexamethasone intravitreal

8 OD

F, 65

Idiopathic vasculitis

None

25 months

Triamcinolone periocular (1×), multiple dexamethasone intravitreal (3×)